Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1

BACKGROUND: Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, is approved in patients with relapsed/refractory multiple myeloma (RRMM) who have previously received an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody. OBJECTIVE: We report the population phar...

Descripción completa

Detalles Bibliográficos
Autores principales: Miao, Xin, Wu, Liviawati S., Lin, Shun Xin Wang, Xu, Yan, Chen, Yang, Iwaki, Yuki, Kobos, Rachel, Stephenson, Tara, Kemmerer, Kristy, Uhlar, Clarissa M., Banerjee, Arnob, Goldberg, Jenna D., Trancucci, Danielle, Apte, Amit, Verona, Raluca, Pei, Lixia, Desai, Rachit, Hickey, Kathleen, Su, Yaming, Ouellet, Daniele, Samtani, Mahesh N., Guo, Yue, Garfall, Alfred L., Krishnan, Amrita, Usmani, Saad Z., Zhou, Honghui, Girgis, Suzette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518021/
https://www.ncbi.nlm.nih.gov/pubmed/37713090
http://dx.doi.org/10.1007/s11523-023-00989-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518021/
https://www.ncbi.nlm.nih.gov/pubmed/37713090
http://dx.doi.org/10.1007/s11523-023-00989-z

Ejemplares similares